COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Compass Pathways faces a critical near-term catalyst with upcoming Phase 3 clinical trial data, which will likely drive significant volatility.
The company is approaching the expected readout for its Phase 3 clinical trial of COMP360 psilocybin treatment for treatment-resistant depression. As this is the primary value driver for the company, the market is highly sensitive to the timing and outcome of these results, which are expected in the near term.
Compass Pathways Investor Relations